Skip to main content

Advertisement

SpringerLink
Log in

Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug?

  • Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

It is now about 40 years ago that the mechanism of renal 1-α-hydroxylation of vitamin D was discovered and characterized. After this seminal observation, the key role of the active vitamin D derivative 1, 25-(OH)2-vitamin D (calcitriol) in calcium homeostasis and bone mineralization, and its specific role in the course of chronic kidney disease (CKD) and renal osteopathy, was unraveled step by step, while the precursor 25-OH-vitamin D (calcidiol) was gradually ignored. Calcitriol and its synthetic analogue alfa-calcidol became the first-line standard drug to tackle secondary hyperparathyroidism (sHPT) in CKD. Potential side-effects, including hypercalcemia, hyperphosphatemia, and vascular calcification, were partly abrogated by developing less calcemic substances such as paricalcitol or maxacalcitol. Thus, TIME Magazine surprised when nominating vitamin D, with regard to its newly discovered pleiotropic actions, as one of the “top medical breakthroughs” in the December issue of 2007. This vote was driven by novel and spectacular insights into the pivotal regulatory role of vitamin D with regard to autoimmune diseases, immune defense, cancer development and progression, and cardiovascular function and disease. More than 30 cell types express the vitamin D receptor (VDR), and more than ten organs in addition to the kidney are capable of paracrine 1-α-hydroxylation. More than 200 genes are under the control of calcitriol. A MEDLINE search performed in December 2009 focusing on the keywords “vitamin D-and-kidney-and-2009” yielded 523 hits. This review intends to give a subjective and CKD-related update on novel biological and clinical insights with relevance to the steroid hormone vitamin D.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Holick M (2007) Vitamin D deficiency. N Engl J Med 357:266–281

    Article  CAS  PubMed  Google Scholar 

  2. Lucas PA, Brown RC, Woodhead JS, Coles GA (1986) 1, 25-dihydroxycholecalciferol and parathyroid hormone in advanced chronic renal failure: effects of simultaneous protein and phosphorous restriction. Clin Nephrol 25:7–10

    CAS  PubMed  Google Scholar 

  3. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C (2009) Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75:88–95

    Article  CAS  PubMed  Google Scholar 

  4. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS (1998) Hypovitaminosis D in medical inpatients. N Engl J Med 338:777–783

    Article  CAS  PubMed  Google Scholar 

  5. Heaney RP, Dowell MS, Hale CA, Bendich A (2003) Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 22:142–146

    CAS  PubMed  Google Scholar 

  6. Heaney RP (2008) Vitamin D in health and disease. Clin J Am Soc Nephrol 3:1535–1541

    Article  CAS  PubMed  Google Scholar 

  7. Holick MF, Biancuzzo RM, Chen TC, Klein EK, Young A, Bibuld D, Reitz R, Salameh W, Ameri A, Tannebaum AD (2008) Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 93:677–681

    Article  CAS  PubMed  Google Scholar 

  8. Armas LAG, Hollis BW, Heaney RP (2004) Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 89:5387–5391

    Article  CAS  PubMed  Google Scholar 

  9. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31–38

    Article  CAS  PubMed  Google Scholar 

  10. Tokmak F, Quack I, Schieren G, Sellin L, Rattensperger D, Holland-Letz T, Weiner SM, Rump LC (2008) High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 23:4016–4020

    Article  CAS  PubMed  Google Scholar 

  11. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2008) Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 23:3670–3676

    Article  CAS  PubMed  Google Scholar 

  12. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, Takasu J, Adler S, Norris K (2008) Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 3:1144–1151

    Article  CAS  PubMed  Google Scholar 

  13. Ozfirat Z, Chowdury TA (2010) Vitamin D deficiency and type 2 diabetes. Postgrad Med J 86:18–25

    Article  CAS  PubMed  Google Scholar 

  14. Menon S, Valentini RP, Hidalgo G, Peschansky L, Mattoo TK (2008) Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol 23:1831–1836

    Article  PubMed  Google Scholar 

  15. Belostotsky V, Mughal MZ, Berry JL, Webb NJ (2008) Vitamin D deficiency in children with renal disease. Arch Dis Child 93:959–962

    Article  CAS  PubMed  Google Scholar 

  16. Seeherunvong W, Abitbol CL, Chandar J, Zilleruelo G, Freundlich M (2009) Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J Pediatr 154:906–911.e1

    Google Scholar 

  17. Ali FN, Arguelles LM, Langman CB, Price HE (2009) Vitamin D deficiency in children with chronic kidney disease: uncovering an epidemic. Pediatrics 123:791–796

    Article  PubMed  Google Scholar 

  18. Prié D, Ureña Torres P, Friedlander G (2009) Latest findings in phosphate homeostasis. Kidney Int 75:882–889

    Article  PubMed  Google Scholar 

  19. Tomida K, Hamano T, Mikami S, Fujii N, Okada N, Matsui I, Nagasawa Y, Moriyama T, Ito T, Imai E, Isaka Y, Rakugi H (2009) Serum 25-hydroxyvitamin D as an independent determinant of 1–84 PTH and bone mineral density in non-diabetic predialysis CKD patients. Bone 44:678–683

    Article  CAS  PubMed  Google Scholar 

  20. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ (2006) 25-hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 70:654–659

    Article  CAS  PubMed  Google Scholar 

  21. Clements MR, Davies M, Hayes ME, Hickey CD, Lumb GA, Mawer EB, Adams PH (1992) The role of 1, 25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol (Oxf) 37:17–27

    Article  CAS  Google Scholar 

  22. Gallieni M, Kamimura S, Ahmed A, Bravo E, Delmez J, Slatopolsky E, Dusso A (1995) Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol 268:F746–F753

    CAS  PubMed  Google Scholar 

  23. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770–1773

    Article  CAS  PubMed  Google Scholar 

  24. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (2005) Estimates of optimal vitamin D status. Osteoporos Int 16:713–716

    Article  CAS  PubMed  Google Scholar 

  25. Segersten U, Correa P, Hewison M, Hellman P, Dralle H, Carling T, Akerström G, Westin G (2002) 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 87:2967–2972

    Article  CAS  PubMed  Google Scholar 

  26. Autier P, Gandini S (2007) Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 167:1730–1737

    Article  CAS  PubMed  Google Scholar 

  27. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W (2008) Independent association of low serum 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 168:1340–1349

    Article  CAS  PubMed  Google Scholar 

  28. Melamed ML, Michos ED, Post W, Astor B (2008) 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168:1629–1637

    Article  PubMed  Google Scholar 

  29. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117:503–511

    Article  CAS  PubMed  Google Scholar 

  30. de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS (2009) 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol 20:1805–1812

    Article  PubMed  Google Scholar 

  31. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Boitte F, Choukroun G, Fournier A, Massy ZA (2009) Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 4:1128–1135

    Article  CAS  PubMed  Google Scholar 

  32. Wang AY, Lam CW, Sanderson JE, Wang M, Chan IH, Lui SF, Sea MM, Woo J (2008) Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr 87:1631–1638

    CAS  PubMed  Google Scholar 

  33. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637–1642

    Article  CAS  PubMed  Google Scholar 

  34. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D on bone density in men and women 65 years of age or older. N Engl J Med 337:670–676

    Article  CAS  PubMed  Google Scholar 

  35. Bischoff-Ferrari HA, Giovannucci E, Willet WC, Dietrich T, Dawson-Hughes B (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84:18–28

    CAS  PubMed  Google Scholar 

  36. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85:1586–1591

    CAS  PubMed  Google Scholar 

  37. Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O’Sullivan MJ, Yasmeen S, Hiatt RA, Shikany JM, Vitolins M, Khandekar J, Hubbell FA, Women’s Health Initiative Investigators (2008) Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 100:1581–1591

    Article  CAS  PubMed  Google Scholar 

  38. Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, Heckbert SR, Johnson KC, Manson JE, Sidney S, Trevisan M, Women’s Health Initiative Investigators (2007) Calcium/vitamin D supplementation and cardiovascular events. Circulation 115:846–854

    Article  CAS  PubMed  Google Scholar 

  39. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y (2004) Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19:179–184

    Article  CAS  PubMed  Google Scholar 

  40. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernán MA, Camargo CA Jr, Thadhani R (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16:1115–1125

    Article  CAS  PubMed  Google Scholar 

  41. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(4 Suppl 3):S1–201

    Google Scholar 

  42. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK (2005) Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67:1179–1187

    Article  CAS  PubMed  Google Scholar 

  43. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD (2006) Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70:771–780

    Article  CAS  PubMed  Google Scholar 

  44. Naves-Díaz M, Alvarez-Hernández D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, Cannata-Andía JB (2008) Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 74:1070–1078

    Article  PubMed  Google Scholar 

  45. Cozzolino M, Brandenburg V (2009) Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the “U”. Clin Nephrol 71:593–601

    CAS  PubMed  Google Scholar 

  46. Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, Akiba T, Greenwood RN, Kimata N, Levin NW, Piera LM, Saran R, Wolfe RA, Port FK (2009) The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 24:963–972

    Article  CAS  PubMed  Google Scholar 

  47. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF (2009) Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev (4):CD005633

  48. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF (2009) Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev (4):CD008175

  49. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446–456

    Article  CAS  PubMed  Google Scholar 

  50. Liu S, Quarles LD (2007) How fibroblast growth factor 23 works. J Am Soc Nephrol 18:1637–1647

    Article  CAS  PubMed  Google Scholar 

  51. Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, Quarles LD (2007) Role of hyperphosphatemia and 1, 25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 18:2116–2124

    Article  CAS  PubMed  Google Scholar 

  52. Ohnishi M, Nakatani T, Lanske B, Razzaque MS (2009) Reversal of mineral ion homeostasis and soft-tissue calcification of Klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int 75:1166–1172

    Article  CAS  PubMed  Google Scholar 

  53. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205–2215

    Article  CAS  PubMed  Google Scholar 

  54. Urena Torres P, Friedlander G, de Vernejoul MC, Silve C, Prié D (2008) Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int 73:102–107

    Article  CAS  PubMed  Google Scholar 

  55. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592

    Article  PubMed  Google Scholar 

  56. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24:2792–2796

    Article  CAS  PubMed  Google Scholar 

  57. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545–2552

    Article  PubMed  Google Scholar 

  58. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE (2009) Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207:546–551

    Article  CAS  PubMed  Google Scholar 

  59. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229–238

    CAS  PubMed  Google Scholar 

  60. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D (2008) Calcium-independent and 1, 25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 74:170–179

    Article  CAS  PubMed  Google Scholar 

  61. Fryer RM, Rakestraw PA, Nakane M, Dixon D, Banfor PN, Koch KA, Wu-Wong JR, Reinhart GA (2007) Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol 106:76–81

    Article  Google Scholar 

  62. Matthias S, Busch R, Merke J, Mall G, Thomasset M, Ritz E (1991) Effects of 1, 25(OH)2D3 on compensatory renal growth in the growing rat. Kidney Int 40:212–218

    Article  CAS  PubMed  Google Scholar 

  63. Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S, Abe H, Kuze K, Fukatsu A, Kita T, Doi T (2001) A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 158:1733–1741

    Google Scholar 

  64. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC (2008) Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 105:15896–15901

    Article  CAS  PubMed  Google Scholar 

  65. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B (2008) Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 74:1394–1402

    Article  CAS  PubMed  Google Scholar 

  66. Tan X, Wen X, Liu Y (2008) Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 19:1741–1752

    Article  CAS  PubMed  Google Scholar 

  67. Matsui I, Hamano T, Tomida K, Inoue K, Takabatake Y, Nagasawa Y, Kawada N, Ito T, Kawachi H, Rakugi H, Imai E, Isaka Y (2009) Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol Dial Transplant 24:2354–2361

    Article  CAS  PubMed  Google Scholar 

  68. Xiao H, Shi W, Liu S, Wang W, Zhang B, Zhang Y, Xu L, Liang X, Liang Y (2009) 1, 25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway. Am J Nephrol 30:34–43

    Article  PubMed  Google Scholar 

  69. Resnick LM, Müller FB, Laragh JH (1986) Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism Ann Intern Med 105:649–654

    CAS  Google Scholar 

  70. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68:2823–2828

    Article  CAS  PubMed  Google Scholar 

  71. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N (2009) Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 54:647–652

    Article  CAS  PubMed  Google Scholar 

  72. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC (2005) Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 288:E125–E132

    Article  CAS  PubMed  Google Scholar 

  73. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM (2007) Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 104:16810–16815

    Article  CAS  PubMed  Google Scholar 

  74. Repo JM, Rantala IS, Honkanen TT, Mustonen JT, Kööbi P, Tahvanainen AM, Niemelä OJ, Tikkanen I, Rysä JM, Ruskoaho HJ, Pörsti IH (2007) Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int 72:977–984

    Article  CAS  PubMed  Google Scholar 

  75. Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU (2008) Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 149:558–564

    Article  CAS  PubMed  Google Scholar 

  76. Price PA, Omid N, Than TN, Williamson MK (2002) The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 71:356–363

    Article  CAS  PubMed  Google Scholar 

  77. Haffner D, Hocher B, Müller D, Simon K, König K, Richter CM, Eggert B, Schwarz J, Godes M, Nissel R, Querfeld U (2005) Systemic cardiovascular disease in uremic rats induced by 1, 25(OH)2D3. J Hypertens 23:1067–1075

    Article  CAS  PubMed  Google Scholar 

  78. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E (2007) Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 72:709–715

    Article  CAS  PubMed  Google Scholar 

  79. Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M (2008) The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 73:300–307

    Article  CAS  PubMed  Google Scholar 

  80. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA (2008) Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 19:1509–1519

    Article  CAS  PubMed  Google Scholar 

  81. Cardús A, Panizo S, Parisi E, Fernandez E, Valdivielso JM (2007) Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 22:860–866

    Article  PubMed  Google Scholar 

  82. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Girndt M (2005) IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 67:1216–1233

    Article  CAS  PubMed  Google Scholar 

  83. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C (1999) Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55:648–658

    Article  CAS  PubMed  Google Scholar 

  84. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B (2006) Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 47:139–148

    Article  CAS  PubMed  Google Scholar 

  85. Cutolo M, Otsa K, Uprus M, Paolino S, Seriolo B (2007) Vitamin D in rheumatoid arthritis. Autoimmun Rev 7:59–64

    Article  CAS  PubMed  Google Scholar 

  86. Deluca HF, Cantorna MT (2001) Vitamin D: its role and uses in immunology. FASEB J 15:2579–2585

    Article  CAS  PubMed  Google Scholar 

  87. de Abreu DA, Babron MC, Rebeix C, Fontenille J, Yaouanq D, Brassat B, Fontaine F, Clerget-Darpoux F, Jehan F, Feron F (2009) Season of birth and not vitamin D receptor promoter polymorphisms is a risk factor for multiple sclerosis. Mult Scler 15:1146–1152

    Article  Google Scholar 

  88. Lewy H, Rotstein A, Kahana E, Marrosu MG, Cocco E, Laron Z (2008) Juvenile multiple sclerosis similar to type I diabetes mellitus has a seasonality of month of birth which differs from that in the general population. J Pediatr Endocrinol Metab 21:473–437

    PubMed  Google Scholar 

  89. Garland CF, Gorham ED, Mohr SB, Garland FC (2009) Vitamin D for cancer prevention: global perspective. Ann Epidemiol 19:468–483

    Article  PubMed  Google Scholar 

  90. Grant WB, Holick MF (2005) Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev 10:94–111

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Klinikum Coburg GmbH, Ketschendorfer Str. 33, 96450, Coburg, Germany

    Patrick H. Biggar, Orfeas Liangos, Holger Fey & Markus Ketteler

  2. Department of Cardiology, University Hospital Aachen, Aachen, Germany

    Vincent M. Brandenburg

Authors
  1. Patrick H. Biggar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Orfeas Liangos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Holger Fey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vincent M. Brandenburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Markus Ketteler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Ketteler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Biggar, P.H., Liangos, O., Fey, H. et al. Vitamin D, chronic kidney disease and survival: a pluripotent hormone or just another bone drug?. Pediatr Nephrol 26, 7–18 (2011). https://doi.org/10.1007/s00467-010-1526-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-010-1526-x

Keywords

Search

Navigation